FDA Approves Groundbreaking Pill for Postpartum Depression Treatment

The FDA has approved zuranolone, the first oral treatment for postpartum depression. Branded as Zurzuvae, the once-a-day pill is meant to be taken for two weeks and has shown rapid improvement in depression symptoms. Postpartum depression affects an estimated 15% of women after childbirth and can last for months or even years. Previously, the only approved option was an IV infusion. Zuranolone works by rebalancing dysregulated neuronal networks in the brain. The drug carries a boxed warning for side effects such as drowsiness and dizziness, and a risk of suicidal thoughts. It will need to clear a 90-day DEA scheduling process before entering the market. The FDA only approved zuranolone for postpartum depression, not major depressive disorder, citing a lack of evidence.